🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. UP421

    Sana Biotechnology

    Type1diabetes

    phase 1 mab active

    1 trial

  2. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  3. VCTX210A unit

    S.A.

    Diabetes Mellitus

    phase 1 other completed

    1 trial

  4. VCTX211

    S.A.

    Diabetes Mellitus

    phase 1 other terminated

    1 trial

  5. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  6. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  7. Vantictumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  8. Vantictumab combined with paclitaxel

    Mereo BioPharma Group plc

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  9. Vedolizumab SC

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    4 trials

  10. Vedolizumab SC

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  11. Vemurafenib Oral Tablet [Zelboraf]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    phase 1 small molecule active

    1 trial

  12. Venlafaxine 25 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  13. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Abnormalities, Cardiovascular

    phase 1 small molecule completed

    1 trial

  14. WX-UK1 in combination with Capecitabine

    United Therapeutics Europe Ltd

    Advanced Malignancies

    phase 1 small molecule completed

    1 trial

  15. XeriSol glucagon

    Xeris Biopharma Holdings

    Type1diabetes

    phase 1 small molecule completed

    1 trial

  16. YZJ-1139 tablets

    Shanghai University of Traditional Chinese Medicine

    Insomnia

    phase 1 small molecule active

    1 trial

  17. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2-expressing Cancers

    phase 1 small molecule completed

    1 trial

  18. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule active

    1 trial

  19. Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg

    AXIM BIOTECHNOLOGIES, INC.

    Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  20. Zimberelimab

    Arcus Biosciences

    Head and Neck Cancer

    phase 1 small molecule terminated

    1 trial

  21. Zimberelimab

    Arcus Biosciences

    Glioblastoma

    phase 1 small molecule active

    1 trial

  22. Zoloft® 100 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  23. Zolpidem 10 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  24. [11C]APP311

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources